JPMorgan analyst Anne Samuel lowered the firm’s price target on Doximity to $30 from $60 and keeps an Underweight rating on the shares. The analyst says the company has not been immune to macro-cross currents impacting the life sciences space. The firm cites near-term headwinds and a lack of visibility for its caution on the shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DOCS:
